Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: An observational study protocol

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Collins, Jemima T ^a,b   Noble, Simon ^b   Chester, John ^c   Davies, Helen E ^a   Evans, William D ^d   Lester, Jason ^c   Parry, Diane ^a   Pettit, Rebecca J ^d   Byrne, Anthony ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c VELINDRE CANCER CENTRE   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Fitness; Lung cancer; Muscle mass; Physical performance; Sarcopenia

Indexed keywords

ARTICLE; CACHEXIA; DUAL ENERGY X RAY ABSORPTIOMETRY; EXPLORATORY RESEARCH; HUMAN; IMPEDANCE; KARNOFSKY PERFORMANCE STATUS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MUSCLE MASS; NON SMALL CELL LUNG CANCER; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PHYSICAL PERFORMANCE; PREDICTION; PREVALENCE; PROSPECTIVE STUDY; SARCOPENIA; SURGICAL PATIENT; TREATMENT PLANNING; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; INTERDISCIPLINARY COMMUNICATION; LUNG NEOPLASMS; PATIENT CARE PLANNING; QUALITY OF LIFE;

CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INTERDISCIPLINARY COMMUNICATION; LUNG NEOPLASMS; PATIENT CARE PLANNING; PROSPECTIVE STUDIES; QUALITY OF LIFE; SARCOPENIA;

EID: 84937809904     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1565-6     Document Type: Article

References (58)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43.
2. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
3. Coleman MP et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127-38.
4. Office for National Statistics. Cancer survival in England: Patients diagnosed 2005-2009 and followed up to 2010. London: ONS; 2011.
5. Behera M et al. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung Cancer. 2012;77(2):331-8.
6. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86(9):1867-76.
7. Non-Small Cell Lung Cancer Collaborative Group, Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2010(5): p. CD007309.
8. Boxer MM et al. Do multidisciplinary team meetings make a difference in the management of lung cancer? Cancer. 2011;117(22):5112-20.
9. Vinod SK et al. Gaps in optimal care for lung cancer. J Thorac Oncol. 2008;3(8):871-9.
10. Mitchell PL et al. Lung cancer in Victoria: are we making progress? Med J Aust. 2013;199(10):674-9.
11. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer. 2002;38 Suppl 2:S45-50.
12. Sweeney CJ et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001;92(10):2639-47.
13. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
14. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press; 1949.
15. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A(7):1135-41.
16. O'Connell JP et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4(11):1604-14.
17. Sorensen JB et al. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(4):773-5.
18. Dajczman E et al. Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol. 2008;3(10):1133-6.
19. Montoya M et al. Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med. 2006;9(2):309-16.
20. Vinod SK et al. Why do some lung cancer patients receive no anticancer treatment? J Thorac Oncol. 2010;5(7):1025-32.
21. Pemberton L et al. Do treatment decisions made at lung cancer multi-disciplinary team meetings (MDTs) reflect the actual treatment given in practice? Lung Cancer (Amsterdam, Netherlands). 2013;79:S36.
22. Fearon K et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95.
23. Lieffers JR et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;107(6):931-6.
24. Peng PD et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13(7):439-46.
25. van Vledder MG et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99(4):550-7.
26. Prado CM et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629-35.
27. Prado CM et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920-6.
28. Mir O et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7(5):e37563.
29. Huillard O et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108(5):1034-41.
30. Goodpaster BH et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059-64.
31. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50(5):889-96.
32. Baumgartner RN et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755-63.
33. Cruz-Jentoft AJ et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23.
34. Kasymjanova G et al. Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(5):602-7.
35. Sonpavde G et al. Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status. Am J Clin Oncol. 2012;35(2):163-6.
36. Jones LW et al. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer. 2007;55(2):225-32.
37. Granger CL et al. Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: a systematic review of instruments and their measurement properties. BMC Cancer. 2013;13:135.
38. Cress ME et al. Continuous-scale physical functional performance in healthy older adults: a validation study. Arch Phys Med Rehabil. 1996;77(12):1243-50.
39. Mijnarends DM et al. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. J Am Med Dir Assoc. 2013;14(3):170-8.
40. Freiberger E et al. Performance-based physical function in older community-dwelling persons: a systematic review of instruments. Age Ageing. 2012;41(6):712-21.
41. Baracos V, Kazemi-Bajestani SM. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol. 2013;45(10):2302-8.
42. Lukaski HC. Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr. 1987;46(4):537-56.
43. Fearon KC et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24(21):3401-7.
44. Gupta D et al. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in advanced colorectal cancer. Am J Clin Nutr. 2004;80(6):1634-8.
45. Sarhill N et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003;11(10):652-9.
46. Rajasekaran AB et al. Effect of a multidisciplinary lung investigation day on a rapid access lung cancer service. Postgrad Med J. 2006;82(968):414-6.
47. Dunican E et al. Outcomes of patients presenting to a dedicated rapid access lung cancer clinic. Ir Med J. 2011;104(9):265-8.
48. Blake GM, Naeem M, Boutros M. Comparison of effective dose to children and adults from dual X-ray absorptiometry examinations. Bone. 2006;38(6):935-42.
49. Guralnik JM et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-94.
50. Cancer Research UK. Performance status. [cited 2014 09/01/2014]; Available from: http://www.cancerresearchuk.org/cancer-help/about-cancer/cancer-questions/performance-status .
51. Stratton RJ et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. Br J Nutr. 2004;92(5):799-808.
52. Boleo-Tome C et al. Validation of the Malnutrition Universal Screening Tool (MUST) in cancer. Br J Nutr. 2012;108(2):343-8.
53. Gloeckler LA, Eisner MP. Cancer of the Lung., in SEER Survival Monograph: Cancer survival among adults: US SEER Program, 1998-2001. Bethesda, MD: National Cancer Institute; 2007. p. 73-80.
54. National Institute for Health and Clinical Excellence, Lung Cancer: The diagnosis and treatment of lung cancer. NICE clinical guideline 121. 2011, NICE.
55. Knols R et al. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol. 2005;23(16):3830-42.
56. Schmitz KH et al. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1588-95.
57. Andersen C et al. The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue. Eur J Oncol Nurs. 2013;17(3):331-9.
58. Quist M et al. Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study. Lung Cancer. 2012;75(2):203-8.